452 related articles for article (PubMed ID: 35193095)
1. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
2. Data pertaining to aberrant intracellular calcium handling during androgen deprivation therapy in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan P
Data Brief; 2022 Jun; 42():108143. PubMed ID: 35496494
[TBL] [Abstract][Full Text] [Related]
3. CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.
McKerr N; Mohd-Sarip A; Dorrian H; Breen C; A James J; McQuaid S; Mills IG; McCloskey KD
Sci Rep; 2023 Mar; 13(1):4683. PubMed ID: 36949059
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
Gao Y; Li L; Li T; Ma L; Yuan M; Sun W; Cheng HL; Niu L; Du Z; Quan Z; Fan Y; Fan J; Luo C; Wu X
Int J Oncol; 2019 Jun; 54(6):2054-2068. PubMed ID: 31081050
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
14. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
15. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
16. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Chen S; Cai C; Sowalsky AG; Ye H; Ma F; Yuan X; Simon NI; Gray NS; Balk SP
Cancer Res; 2018 Sep; 78(18):5203-5215. PubMed ID: 30012673
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
18.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
20. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.
Wan X; Pu H; Huang W; Yang S; Zhang Y; Kong Z; Yang Z; Zhao P; Li A; Li T; Li Y
Oncotarget; 2016 Aug; 7(32):51284-51300. PubMed ID: 27323416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]